Search for in this collection

Subscribe to this collection to receive daily e-mail notification of new additions

Preview	Issue Date	Title / Name	Author(s)
	Mar-2021	High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial	Nair-Shalliker, V.; Smith, D.P.; Gillatt, D.; Gurney, H.; Patel, M.I.; Woo, H.; Rasiah, K.; Symons, J.; Gebski, V.; Espinoza, D.; Frydenberg, M.; Yaxley, J.W.; Gardiner, R.; Kimlin, M.G.; Fenech, M.; Armstrong, B.K.; Rasiah, K.; Awad, N.; Awad, N.
	Jun-2020	Implementation of advanced radiotherapy technology to improve clinical outcomes in rural NSW	Banjade, D.; Allan, J.; Thuraisingam, K.; Mishra, A.; Newham, B.; Tan, S. J. E.; Renshaw, A.; Hammond, R.; Stevens, G.; Warr, G.; Warr, George
	1996	Is measurement of total body nitrogen (TBN) a useful predictor of chemotherapy (C/T) toxicity in breast cancer?	Aslani, A.; Begbie, S.; Smith, R. C.; Alle, B. J.; Begbie, Stephen
	Sep-2007	Chemotherapy in the treatment of prostate cancer--is there a role?	Arianayagam, M.; Chang, J.; Rashid, P.; Arianayagam, Mohan; Chang, Jeff; Rashid, Prem
	Dec-2013	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial	Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; Efstathiou, E.; Oudard, S.; Morris, M. J.; Goebell, P. J.; Heidenreich, A.; de Bono, J. S.; Begbie, S.; et. al; Begbie, Stephen
	Aug-2023	Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial	Antonarakis, E.; Park, S. H.; Goh, J. C.; Shin, S. J.; Lee, J. L.; Mehra, N.; Dermott, R.; Sala-Gonzalez, N.; Fong, P. C.; Greil, R.; Retz, M.; Sade, J. P.; Yanez, P.; Huang, Y.; Begbie, S. D.; et. al; Begbie, Stephen
	Sep-2023	Chronic lymphocytic leukaemia Australasian consensus practice statement	Anderson, Mary A.; Bennett, R.; Badoux, X.; Best, G.; Chia, N.; Cochrane, T.; Cull, G.; Crassini, K.; et. al; Crassini, Kyle
	Oct-2016	IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report	Greuter, T.; Browne, M.; Dommann-Scherrer, C.; Binder, D.; Renner, C.; Kapp, U.; Browne, Martin
	Dec-2009	Mapping oncology services in regional and rural Australia	Underhill, C.; Bartel, R.; Goldstein, D.; Snodgrass, H.; Begbie, S.; Yates, P.; White, K.; Jong, K.; Grogan, P.; Begbie, Stephen
	Jul-2007	Improving access to radiotherapy for regional cancer patients-the National Radiotherapy Single Machine Unit Trial	Turner, M. B.; Shakespeare, T.; Chapman, A.; Shakespeare, Thomas P.
	Mar-2021	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status	Travers, A.; Jalali, A.; Begbie, S.; Semira, C.; Kosmider, S.; Ananda, S.; Wong, R.; Lee, M.; Shapiro, J.; Burge, M.; Yip, D.; Torres, J.; Ma, B.; Nott, L.; Dean, A.; Tie, J.; Khattak, A.; Lim, S.; Wong, H. L.; Gibbs, P.; Begbie, Stephen
	Aug-2008	RANZCR 2006 peer review audit instrument	Toohey, J.; Shakespeare, T. P.; Morgan, G.; Toohey, Joanne; Shakespeare, Thomas P.
	Nov-2022	Survival outcomes associated with Lynch syndrome colorectal cancer and metachronous rate after subtotal/total versus segmental colectomy: Meta-analysis	Toh, J. W. T.; Hui, N.; Collins, G.; Phan, K.; Hui, Nicholas
	Oct-2019	Validation of the prognostic ability of the five-tiered ISUP grade groups for prostate cancer treated with definitive dose-escalated external beam radiation treatment in a contemporary Australian population	Toby, J.; Shakespeare, T. P.; Aherne, N.; Brown, C.; Guo, L.; Hoffman, M.; Hruby, G.; Kneebone, A.; Eade, T.; Shakespeare, Thomas P.; Aherne, Noel; Hoffmann, Matthew
	Sep-2021	Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation	Toby, J.; Eade, T.; Hruby, G.; Kneebone, A.; Aherne, N.; Brown, C.; Guo, L.; Hoffmann, M.; Shaekspeare, T. P.; Aherne, Noel; Hoffmann, Matthew; Shakespeare, Thomas P.
	Oct-2009	Prostate-specific antigen velocity (PSAV): a practical role for PSA?	Thanigasalam, R.; Mancuso, P.; Tsao, K.; Rashid, P.; Thanigasalam, Ruban; Rashid, Prem
	Feb-2007	The role of palliative radiation therapy in symptomatic locally advanced gastric cancer	Tey, J.; Back, M. F.; Shakespeare, T. P.; Mukherjee, R. K.; Lu, J. J.; Lee, K. M.; Wong, L. C.; Leong, C. N.; Zhu, M.; Shakespeare, Thomas P.
	Dec-2019	Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion	Te Velde, B. L.; Westhuyzen, J.; Awad, N.; Wood, M.; Shakespeare, T. P.; Te Velde, Bridget L.; Westhuyzen, Justin; Awad, Nader; Wood, Maree; Shakespeare, Thomas P.
	Aug-2017	Can a peri-rectal hydrogel spaceOAR programme for prostate cancer intensity-modulated radiotherapy be successfully implemented in a regional setting?	Te Velde, B. L.; Westhuyzen, J.; Awad, N.; Wood, M.; Shakespeare, T. P.; Te Velde, Bridget L.; Westhuyzen, Justin; Awad, Nader; Wood, Maree; Shakespeare, Thomas P.
	Aug-2008	Craniospinal dissemination in teratocarcinosarcoma	Tchoyoson Lim, C. C.; Thiagarajan, A.; Sim, C. S.; Khoo, M. L.; Shakespeare, T. P.; Ng, I.; Shakespeare, Thomas P.